CMPS, Trump and Compass Pathways
Digest more
Compass Pathways may be the first to benefit from an accelerated approval process.
Investor's Business Daily on MSN
How Trump sent psychedelics-tied Compass Pathways and others flying
Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.
Towards that end in 2018, it received FDA's Breakthrough Therapy designation for COMP360 in the treatment of TRD. In 11/2021 it announced positive results from its phase 2b trial which was written up in an 11/2022 article in NEJM. In 2025, it commenced a pivotal trial program for COMP360. It consisted of:
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Investors look at many variables when deciding which stocks to buy, including a company's industry. If an industry is exhibiting high growth, many stocks in that sector can gain value. A rising tide lifts all boats, and that trend is playing out for ...
It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy designation from ...
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can be greeted with notable share price pops. Compass ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.
Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 synthetic psilocybin in treatment-resistant depression and advanced a rolling FDA submission.